CytoSorbents Corp. (CTSO)

4.58
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 4.58
Open 4.55
Day Low/High 4.53 / 4.66
52 Wk Low/High 3.68 / 12.00
Volume 49.28K
Avg Volume 178.90K
Exchange NASDAQ
Shares Outstanding 32.30M
Market Cap 143.43M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

4 Stocks Rising on Unusual Volume to Trade for Breakouts

4 Stocks Rising on Unusual Volume to Trade for Breakouts

These stocks rising on unusual volume are within range of triggering breakout trades.

Relative Strength Alert For Cytosorbents

Relative Strength Alert For Cytosorbents

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

4 Stocks Spiking on Big Volume: Arista Networks and More

4 Stocks Spiking on Big Volume: Arista Networks and More

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech columnist Adam Feuerstein answers readers' questions about health care.

CytoSorbents CEO Provides Exclusive Interview With MedGadget

CytoSorbents CEO Provides Exclusive Interview With MedGadget

Dr. Phillip Chan Discusses the Potential of CytoSorb(R) to Revolutionize Critical Care Medicine, the Strategy in Europe, and Plans for a US Pivotal Study

CytoSorbents Provides Corporate Update And Reports 2012 Year End Financial Results

CytoSorbents Provides Corporate Update And Reports 2012 Year End Financial Results

Q1 2013 CytoSorb(R) Product Revenue to Exceed Entire 2012 CytoSorb(R) Product Revenue

Photo Release -- CytoSorbents Provides Update On ISICEM 2013 Critical Care Conference

Photo Release -- CytoSorbents Provides Update On ISICEM 2013 Critical Care Conference

Significant Interest Generated from Distributors and Key Opinion Leaders